+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Potential of oncolytic viruses in the treatment of multiple myeloma



Potential of oncolytic viruses in the treatment of multiple myeloma



Oncolytic ViroTherapy 7: 1-12



Multiple myeloma (MM) is a clonal malignancy of plasma cells that is newly diagnosed in ~30,000 patients in the US each year. While recently developed therapies have improved the prognosis for MM patients, relapse rates remain unacceptably high. To overcome this challenge, researchers have begun to investigate the therapeutic potential of oncolytic viruses as a novel treatment option for MM. Preclinical work with these viruses has demonstrated that their infection can be highly specific for MM cells and results in impressive therapeutic efficacy in a variety of preclinical models. This has led to the recent initiation of several human trials. This review summarizes the current state of oncolytic therapy as a therapeutic option for MM and highlights a variety of areas that need to be addressed as the field moves forward.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065419909

Download citation: RISBibTeXText

PMID: 29503813

DOI: 10.2147/ov.s136644


Related references

Oncolytic Viruses for Multiple Myeloma Therapy. Cancers 10(6):, 2018

Engineering measles virus as an oncolytic agent for the treatment of multiple myeloma. Blood 96(11 Part 1): 512a, 2000

PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncology Reports 31(4): 1581-1588, 2014

Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Therapy 15(10): 797-806, 2008

Oncolytic virotherapy for multiple myeloma. Expert Opinion on Biological Therapy 8(4): 463-473, 2008

Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Immunology & Cell Biology. 73(4): 326-332, 1995

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101(7): 2557-2562, 2003

Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. British Journal of Haematology 137(2): 133-141, 2007

Oncolytic virotherapy for multiple myeloma: past, present, and future. Bone Marrow Research 2011: 632948, 2011

A retrospective analysis of ten symptomatic multiple myeloma patients with HIV infection: a potential therapeutic effect of HAART in multiple myeloma. Leukemia Research 38(9): 1079-1084, 2014

Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clinical Cancer Research 18(17): 4850-4860, 2012

Oncolytic viruses for potential osteosarcoma therapy. Advances in Experimental Medicine and Biology 804: 259-283, 2014

Unleashing the therapeutic potential of oncolytic viruses. Journal of Clinical Investigation 128(4): 1258-1260, 2018

Potential and clinical translation of oncolytic measles viruses. Expert Opinion on Biological Therapy 17(3): 353-363, 2017

Potential of tumour cells for delivering oncolytic viruses. Gene Therapy 15(10): 704-710, 2008